These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

358 related items for PubMed ID: 23508058

  • 1. Complement and kidney disease.
    Cook HT.
    Curr Opin Nephrol Hypertens; 2013 May; 22(3):295-301. PubMed ID: 23508058
    [Abstract] [Full Text] [Related]

  • 2. Treatment of Rare Inflammatory Kidney Diseases: Drugs Targeting the Terminal Complement Pathway.
    Anliker-Ort M, Dingemanse J, van den Anker J, Kaufmann P.
    Front Immunol; 2020 May; 11():599417. PubMed ID: 33362783
    [Abstract] [Full Text] [Related]

  • 3. Complement in glomerular diseases.
    Tan Y, Zhao MH.
    Nephrology (Carlton); 2018 Oct; 23 Suppl 4():11-15. PubMed ID: 30298653
    [Abstract] [Full Text] [Related]

  • 4. Targeting the complement cascade: novel treatments coming down the pike.
    Thurman JM, Le Quintrec M.
    Kidney Int; 2016 Oct; 90(4):746-52. PubMed ID: 27325183
    [Abstract] [Full Text] [Related]

  • 5. Complement and glomerular disease: new insights.
    Pickering M, Cook HT.
    Curr Opin Nephrol Hypertens; 2011 May; 20(3):271-7. PubMed ID: 21422921
    [Abstract] [Full Text] [Related]

  • 6. Atypical hemolytic uremic syndrome: from the rediscovery of complement to targeted therapy.
    Fakhouri F, Frémeaux-Bacchi V, Loirat C.
    Eur J Intern Med; 2013 Sep; 24(6):492-5. PubMed ID: 23756030
    [Abstract] [Full Text] [Related]

  • 7. Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference.
    Goodship TH, Cook HT, Fakhouri F, Fervenza FC, Frémeaux-Bacchi V, Kavanagh D, Nester CM, Noris M, Pickering MC, Rodríguez de Córdoba S, Roumenina LT, Sethi S, Smith RJ, Conference Participants.
    Kidney Int; 2017 Mar; 91(3):539-551. PubMed ID: 27989322
    [Abstract] [Full Text] [Related]

  • 8. Eculizumab in the treatment of atypical haemolytic uraemic syndrome and other complement-mediated renal diseases.
    Nester CM, Brophy PD.
    Curr Opin Pediatr; 2013 Apr; 25(2):225-31. PubMed ID: 23486421
    [Abstract] [Full Text] [Related]

  • 9. C5 inhibition prevents renal failure in a mouse model of lethal C3 glomerulopathy.
    Williams AL, Gullipalli D, Ueda Y, Sato S, Zhou L, Miwa T, Tung KS, Song WC.
    Kidney Int; 2017 Jun; 91(6):1386-1397. PubMed ID: 28139294
    [Abstract] [Full Text] [Related]

  • 10. Complement and glomerular diseases.
    Popat RJ, Robson MG.
    Nephron Clin Pract; 2014 Jun; 128(3-4):238-42. PubMed ID: 25412932
    [Abstract] [Full Text] [Related]

  • 11. Novel roles of complement in renal diseases and their therapeutic consequences.
    Wada T, Nangaku M.
    Kidney Int; 2013 Sep; 84(3):441-50. PubMed ID: 23615508
    [Abstract] [Full Text] [Related]

  • 12. Anti-complement therapy for glomerular diseases.
    Bomback AS.
    Adv Chronic Kidney Dis; 2014 Mar; 21(2):152-8. PubMed ID: 24602464
    [Abstract] [Full Text] [Related]

  • 13. The emerging role of complement inhibitors in transplantation.
    Frémeaux-Bacchi V, Legendre CM.
    Kidney Int; 2015 Nov; 88(5):967-73. PubMed ID: 26376132
    [Abstract] [Full Text] [Related]

  • 14. Posttransplant recurrence of atypical hemolytic uremic syndrome.
    Valoti E, Alberti M, Noris M.
    J Nephrol; 2012 Nov; 25(6):911-7. PubMed ID: 22760880
    [Abstract] [Full Text] [Related]

  • 15. Complement dysfunction in hemolytic uremic syndrome.
    Zipfel PF, Skerka C.
    Curr Opin Rheumatol; 2006 Sep; 18(5):548-55. PubMed ID: 16896298
    [Abstract] [Full Text] [Related]

  • 16. Molecules Great and Small: The Complement System.
    Mathern DR, Heeger PS.
    Clin J Am Soc Nephrol; 2015 Sep 04; 10(9):1636-50. PubMed ID: 25568220
    [Abstract] [Full Text] [Related]

  • 17. Therapeutic regulation of complement in patients with renal disease - where is the promise?
    Thurman JM.
    Clin Nephrol; 2012 May 04; 77(5):413-23. PubMed ID: 22551888
    [Abstract] [Full Text] [Related]

  • 18. Recent advances in the management of atypical hemolytic uremic syndrome.
    Cataland SR.
    Clin Adv Hematol Oncol; 2012 Aug 04; 10(8):537-9. PubMed ID: 23073053
    [No Abstract] [Full Text] [Related]

  • 19. Treatment of C3 glomerulopathy with complement blockers.
    Vivarelli M, Emma F.
    Semin Thromb Hemost; 2014 Jun 04; 40(4):472-7. PubMed ID: 24799307
    [Abstract] [Full Text] [Related]

  • 20. Defective complement inhibitory function predisposes to renal disease.
    Java A, Atkinson J, Salmon J.
    Annu Rev Med; 2013 Jun 04; 64():307-24. PubMed ID: 23121180
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.